

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Previously presented): A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject, in an amount effective for said treatment, (a) an antibody that (i) immunospecifically binds CD30 and (ii) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line, wherein said antibody exerts the cytostatic or cytotoxic effect on the Hodgkin's Disease cell line in the absence of conjugation to a cytostatic or cytotoxic agent and in the absence of cells other than cells of said Hodgkin's Disease cell line; and (b) a pharmaceutically acceptable carrier.

2. (Original): The method of claim 1, wherein the antibody is human, humanized or chimeric.

3. (Original): The method of claim 1, further comprising administering chemotherapy to said subject.

4. (Original): The method of claim 1, wherein the antibody is conjugated to a cytotoxic agent.

5. (Currently amended): The method of claim 1, wherein the antibody is a fusion protein comprising an antigen binding region that immunospecifically binds to CD30 and an amino acid sequence of a second protein that is not an antibody.

6. (Original): The method of claim 4 or 5, further comprising administering chemotherapy to said subject.

7. (Currently amended): The method of claim 1, wherein the cytostatic or cytotoxic effect of the antibody is exhibited upon performing a method comprising:

- (a) contacting a culture of the Hodgkin's Disease cell line with the antibody, said culture being of about 5,000 cells in a culture area of about 0.33 cm², said contacting being for a period of 72 hours;
- (b) exposing the culture to 0.5 µCi of ³H-thymidine during the final 8 hours of said 72 hour ~~72-hour~~ period; and
- (c) measuring the incorporation of the ³H-thymidine into cells of the culture,

wherein the antibody has a cytostatic or cytotoxic effect on the Hodgkin's Disease cell line if the cells of the culture have reduced ^3H -thymidine incorporation compared to cells of the same Hodgkin's Disease cell line cultured under the same conditions but not contacted with the antibody.

8. (Currently amended): A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject an amount of an antibody, ~~a protein~~, which antibody protein (a) competes for binding to CD30 with monoclonal antibody AC10 or HeFi-1, and (b) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line in the absence of cells other than cells of said Hodgkin's Disease cell line, which amount is effective for the treatment of Hodgkin's Disease.

9-10. (Canceled)

9 ~~11~~. (Currently amended): A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject an amount of an antibody, ~~a protein~~, which antibody protein (a) comprises the ~~an~~ amino acid sequence that has at least 95% identity to SEQ ID NO:2, (b) immunospecifically binds CD30, and (c) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line in the absence of cells other than cells of said Hodgkin's Disease cell line, which amount is effective for the treatment of Hodgkin's Disease.

10 ~~12~~. (Canceled)

11 ~~13~~. (Currently amended): The method of any one of claims 8 or ~~11~~, wherein the antibody protein is a human, humanized or chimeric antibody.

12 ~~14~~. (Previously presented): The method of any one of claims 8 or ~~11~~, further comprising administering chemotherapy to said subject.

13 ~~15~~. (Currently amended): The method of any one of claims 8 or ~~11~~, wherein the antibody protein is conjugated to a cytotoxic agent.

14 ~~16~~. (Currently amended): The method of any one of claims 8 or ~~11~~, wherein the antibody protein is fusion protein comprising an antigen binding region that immunospecifically binds to CD30 and the amino acid sequence of a second protein.

15 ~~17~~. (Original): The method of claim ~~13~~, further comprising administering chemotherapy to the subject.

¹⁶18. (Previously presented): The method of claim ¹⁴16, further comprising administering chemotherapy to the subject.

¹⁷19. (Currently amended): The method of any one of claims 8 or ⁹11, wherein the cytostatic or cytotoxic effect is exhibited upon performing a method comprising:

- (a) contacting a culture of the Hodgkin's Disease cell line with the antibody, ~~protein~~, said culture being of about 5,000 cells in a culture area of about 0.33 cm², said contacting being for a period of 72 hours;
- (b) exposing the culture to 0.5 µCi of ³H-thymidine during the final 8 hours of said 72 hour ~~72-hour~~ period; and
- (c) measuring the incorporation of the ³H-thymidine into cells of the culture, wherein the antibody ~~protein~~ has a cytostatic or cytotoxic effect on the Hodgkin's Disease cell line if the cells of the culture have reduced ³H-thymidine incorporation compared to cells of the same Hodgkin's Disease cell line cultured under the same conditions but not contacted with the antibody. ~~protein~~.

20-66. (Canceled)

¹⁸67. (Currently amended) A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject, in an amount effective for said treatment, (a) an antibody that (i) immunospecifically binds CD30 and (ii) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line, wherein the antibody exerts the cytostatic or cytotoxic effect on the Hodgkin's Disease cell line in the absence of conjugation to a cytostatic or cytotoxic agent and (b) a pharmaceutically acceptable carrier,

wherein the cytostatic or cytotoxic effect of the antibody is exhibited upon performing a method comprising:

- (A) immobilizing said antibody in a well, said well having a culture area of about 0.33 cm²;
- (B) adding about 5,000 cells of the Hodgkin's Disease cell line in the presence of RPMI with 20% fetal bovine serum to the well:

(C) culturing the cells in the presence of said antibody and RPMI with 20% fetal bovine serum for a period of 72 hours to form a Hodgkin's Disease cell culture;

(D) exposing the Hodgkin's Disease cell culture to 0.5 μ Ci/well of 3 H-thymidine during the final 8 hours of said 72 hour ~~72-hour~~ period; and

(E) measuring the incorporation of the 3 H-thymidine into cells of the Hodgkin's Disease cell culture,

wherein the antibody has a cytostatic or cytotoxic effect on the Hodgkin's Disease cell line if the cells of the Hodgkin's Disease cell culture have reduced

3 H-thymidine incorporation compared to cells of the same Hodgkin's Disease cell line cultured under the same conditions but not contacted with the antibody.

1968. (New): A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject, in an amount effective for said treatment, (a) a chimeric, humanized or human antibody that (i) immunospecifically binds CD30 and (ii) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line, wherein the chimeric, humanized or human antibody exerts the cytostatic or cytotoxic effect on the Hodgkin's Disease cell line in the absence of conjugation to a cytostatic or cytotoxic agent and (b) a pharmaceutically acceptable carrier,

wherein the cytostatic or cytotoxic effect of the chimeric, humanized or human antibody is exhibited upon performing a method comprising:

(A) contacting a culture of the Hodgkin's Disease cell line with the chimeric, humanized or human antibody, said culture being of about 5,000 cells in a culture area of about 0.33 cm², said contacting being for a period of 72 hours;

(B) adding a cross-linking antibody to the Hodgkin's Disease cell line, the cross-linking antibody binding to the chimeric, humanized or human antibody;

(C) exposing the culture to 0.5 μ Ci of 3 H-thymidine during the final 8 hours of said 72-hour period; and

(D) measuring the incorporation of the 3 H-thymidine into cells of the culture, wherein the chimeric, humanized or human antibody has a cytostatic or cytotoxic effect on the Hodgkin's Disease cell line if the cells of the culture have reduced

³H-thymidine incorporation compared to cells of the same Hodgkin's Disease cell line cultured under the same conditions but not contacted with the chimeric, humanized or human antibody.